New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Cytokinetics, Incorporated
CYTK
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

6B

Biotechnology

Next Earning date - 14 May 2025

6B

Biotechnology

Next Earning date - 14 May 2025

45.43USD

Shape2.33 ( 5.41%)
moonAfter-hours 43.45$arrow-right-up0.02 (0.05%)
Market Closed (as of Mar 21, 20:00 EDT)
favorite-chart

Relative Strenght

24
favorite-chart

Volume Buzz

141%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

40%

Quote Panel

Shape
Updated March 24, 2025
1W 7.60 % 1M -0.17 % 3M -4.06 % 1Y -32.24 %

Key Metrics

Shape
  • Market Cap

    5.51B


  • Shares Outstanding

    118.41M


  • Share in Float

    115.43M


  • Dividende

    0


  • Earning Date

    14 May 2025


  • Price Target

    46.57


  • Average Volume

    1.55M


  • Beta

    0.951


  • Range

    40.53-75.71


  • Industry

    Biotechnology


  • Website

    https://www.cytokinetics.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

291.19x

P/S Ratio

-37.58x

P/B Ratio

-5.8

Debt/Equity

-3191.1%

Net Margin

$-5.3

EPS

How CYTK compares to sector?

P/E Ratio

Relative Strength

Shape

CYTK

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$37M

Shape120%

2025-Revenue

$5.72

Shape-327%

2025-EPS

$37M

Shape70%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

67.00(43.87%)

Number of analyst

1

Last analyst upgrade/downgrade

Goldman Sachs

downgrade

Previous: Not converted

2024-08-13

Now: Neutral

Cantor Fitzgerald

initialise

Previous: Not converted

2023-08-15

Now: Overweight

Barclays

initialise

Previous: Not converted

2023-08-15

Now: Overweight

Oppenheimer

initialise

Previous: Not converted

2023-08-15

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q1.23

arrow
arrow

N/A

-1.38
vs -1.02

Q2.23

arrow
arrow

N/A

-1.34
vs -0.23

Q3.23

arrow
arrow

N/A

-1.35
vs -1.28

Q4.23

arrow
arrow

N/A

-1.38
vs -1.45

Q1.24

arrow
arrow

N/A

-1.33
vs -1.38

Q2.24

arrow
arrow

N/A

-1.31
vs -1.34

Q3.24

arrow
arrow

N/A

-1.36
vs -1.35

Q4.24

arrow
arrow

N/A

-1.26
vs -1.38

Q1.25

arrow
arrow

N/A

-1.37
vs -1.33

Q2.25

arrow
arrow

N/A

-1.42
vs -1.31

Sales GrowthShape

status-upYoY

Current

Estimates

Q1.23

arrow
arrow

+302%

4.6M  vs 1.1M

Q2.23

arrow
arrow

-99%

867K  vs 89M

Q3.23

arrow
arrow

-85%

378K  vs 2.5M

Q4.23

arrow
arrow

-15%

1.7M  vs 2M

Q1.24

arrow
arrow

-82%

835K  vs 4.6M

Q2.24

arrow
arrow

-71%

249K  vs 867K

Q3.24

arrow
arrow

+22%

463K  vs 378K

Q4.24

arrow
arrow

+912%

16.9M  vs 1.7M

Q1.25

arrow
arrow

+331%

3.6M  vs 835K

Q2.25

arrow
arrow

+989%

2.7M  vs 249K

Return on EquityShape

status-upQoQ

Q1.23

arrow
arrow

+57%

0.57
vs 1.22

Q2.23

arrow
arrow

+39%

0.39
vs 0.57

Q3.23

arrow
arrow

+29%

0.29
vs 0.39

Q4.23

arrow
arrow

+35%

0.35
vs 0.29

Q1.24

arrow
arrow

+34%

0.34
vs 0.35

Q2.24

arrow
arrow

-132%

-1.32
vs 0.34

Q3.24

arrow
arrow

+1154%

11.54
vs -1.32

Q4.24

arrow
arrow

+111%

1.11
vs 11.54

Institutionnal OwnershipShape

status-upQoQ

Q1.23

arrow
arrow

271

271
vs 293

-8%

Q2.23

arrow
arrow

268

268
vs 271

-1%

Q3.23

arrow
arrow

281

281
vs 268

5%

Q4.23

arrow
arrow

428

428
vs 281

52%

Q1.24

arrow
arrow

457

457
vs 428

7%

Q2.24

arrow
arrow

392

392
vs 457

-14%

Q3.24

arrow
arrow

395

395
vs 392

1%

Q4.24

arrow
arrow

378

378
vs 395

-4%

Earnings Growth

Latest News